Salvage chemotherapy in metastatic breast cancer: An experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin

Breast Cancer Research and Treatment

Volumn 38, Issue 3, 1996, Pages 277-282

  Colozza, Mariantonietta ^a,c   Gori, Stefania ^a   Mosconi, Anna Maria ^a   Anastasi, Paola ^a   Basurto, Carlo ^a   Ludovini, Vienna ^a   De Angelis, Verena ^b   Giansanti, Michele ^b   Tonato, Maurizio ^a  

^a Policlinico Hospital   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Policlinico Hospital   (Italy)

Author keywords

5 fluorouracil and leucovorin combination; Metastatic breast cancer; Mitoxantrone; Salvage chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; FEVER; HAIR LOSS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; SALVAGE THERAPY;

EID: 0029991435     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806146     Document Type: Article

References (30)

1. Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC: Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med 84: 389-392, 1976
2. Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP, Falkson HC: The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin and 5-fluoruracil (CAF) in patients with metastatic breast cancer. Cancer 56: 219-224, 1985
3. Eddy DM: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10: 657-670, 1992
4. Landys K, Borgstrom S, Anderson T, Noppa H: Mitoxantrone as a first-line treatment of advanced breast cancer. Invest New Drugs 3: 133-137, 1985
5. Smith IE, Stuart-Harris R, Pavlidis N, Bozek T: Mitoxantrone as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rev 10: 37-40, 1983
6. Mouridsen HT, Cornbleet M, Stuart-Harris R, Smith I, Coleman R, Rubens R, McDonald M, Rainer H, van Oosterom A, Smyth J: Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a Collaborative European Study. Invest New Drugs 3: 139-148, 1985
7. Smyth IE, Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, McDonald M, Mouridsen HT, Rainer H, van Oosterom AT: Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European Collaborative Study. Sem Oncol 11: 15-18, 1984
8. Shenkenberg TD, Von Hoff DD: Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105: 67-81, 1986
9. Neidhart JA, Gachnour D, Roach R, Hoth D, Young D: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 672-677, 1986
10. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560-571, 1989
11. Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Golberg D, Blayney D, Odujinrin O, DeLap R, Shuster J, Newman E: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8: 491-501, 1990
12. Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kalser MH, Barkin JS, Benedetto P, Woolley PV, Nauta R, Weaver DW, Leichman LP: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989
13. Swain SM, Lippmann ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ: Fluorouracil and high-dose leucovorin in previously treated patients with melastatic breast cancer. J Clin Oncol 7: 890-899, 1989
14. Doroshow JH, Leong L, Margolin K, Flanagan B, Goldberg D, Bertrand M, Akman S, Carr B, Odujinrin O, Newman E, Litchfield T: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7: 439-444, 1989
15. Loprinzi CL, Ingle JN, Schaid DJ, Bukner JC, Edmond JH, Allegra CJ: 5-fluorouracil plus leucovorin in women with metastatic breast cancer. Am J Clin Oncol 14: 30-32, 1991
16. Fine S, Erlichman C, Kaizer L, Warr D, Elhakim T: Phase II trial of 5-FU + folinic acid (FA) as first line treatment for metastatic breast cancer. Proc Am Soc Clin Oncol 7: 41, 1988
17. Hainsworth DJ, Andrews MB, Johnson DH, Greco A: Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 9: 1731-1733, 1991
18. Jones SE, Mennel RG, Brooks B, Westrick MA, Allison A, Paulson RS, Tilmann K, Rea B: Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9: 1736-1739, 1991
19. Newman EM, Straw JA, Doroshow JH: Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (Leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res 49: 5755-5760, 1989
20. Machover D, Grison X, Goldschmidt E, Zittoun J, Lotz JP, Metzger G, Richaud J, Hannoun L, Marquet J, Guillot T, Salmon R, Sezeur A, Mauban S, Parc R, Izrael V: Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: A Phase I-II study. J Natl Cancer Inst 84: 321-327, 1992
21. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
22. Roila F, Basurto C, Minotti V, Ballatori E, Tonato M: A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 18: 88-89, 1986
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1958
24. Wils JA: Mitoxantrone, leucovorin and high-dose infusional 5-fluorouracil: an effective and well-tolerated regimen for the treatment of advanced breast cancer. Eur J Cancer 29A (15): 2106-2108, 1993
25. Repetto L, Miglietta L, Gardin G, Lanfranco C, Naso C, Merlini L, Giudici S, Venturino A, Campora E, Testore F, Rosso R: Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. Breast Cancer Res Treat 30: 133-137, 1994
26. Swain S, Honig S, Johnson K, Egan E, Walton L, Pickle L, Tefft M, George M, Vincenti T: A mitoxantrone, 5-fluorouracil and high dose leucovorin regimen as treatment for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 10: 54, 1991
27. Bonadonna G, Valagussa P: Chemotherapy of breast cancer. Current views and results. Int J Radiat Oncol Biol Phys 9: 279-297, 1983
28. Hortobagyi GN: Salvage chemotherapy for metastatic breast cancer. Sem Hematol 24: 56-61, 1987
29. Belanger K, Dionne J, Yelle L, Biais M, Ayoub J, Jolivet J: First-line combination chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil and high dose leucovorin. Proc Am Soc Clin Oncol 9: 31, 1990
30. Carmo-Pereira J, Costa FO, Henriques E: Mitoxantrone, folinic acid, 5-fluorouracil and prednisone, as first-line chemotherapy in advanced breast cancer. A phase II study. Proc Am Soc Clin Oncol 10: 50, 1991